MUC16 and ovarian carcinoma: The ROMA has a higher sensitivity and specificity for the prediction of ovarian cancer in patients with pelvic masses compared to CA125 alone, allowing it to distinguish the risk of a patient with benign (low risk) and malignant (high risk) conditions, which can improve the early detection of ovarian cancer.